Interactions : אינטראקציות

9        drug interactions
9.1      Effect of Other Drugs on ORSERDU
Strong and Moderate CYP3A4 Inhibitors
Avoid concomitant use of strong or moderate CYP3A inhibitors with ORSERDU.
Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inhibitor including grapefruit or grapefruit juice increase elacestrant exposure [see Clinical Pharmacology (13.3)], which may increase the risk of adverse reactions of ORSERDU.
Strong and Moderate CYP3A4 Inducers
Avoid concomitant use of strong or moderate CYP3A inducers with ORSERDU.
Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inducer decreases elacestrant exposure [see Clinical Pharmacology (13.3)], which may decrease effectiveness of ORSERDU.
9.2      Effect of ORSERDU on Other Drugs
P-gp Substrates
Reduce the dosage of P-gp substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.
Elacestrant is a P-gp inhibitor. Concomitant use of ORSERDU with a P-gp substrate increased the concentrations of P-gp substrate [see Clinical Pharmacology (13.3)], which may increase the adverse reactions associated with a P-gp substrate.
BCRP Substrates
Reduce the dosage of BCRP substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.



Elacestrant is a BCRP inhibitor. Concomitant use of ORSERDU with a BCRP substrate increased the plasma concentrations of BCRP substrate [see Clinical Pharmacology (13.3)], which may increase the adverse reactions associated with a BCRP substrate.